Zobrazeno 1 - 10
of 2 869
pro vyhledávání: '"physiologically-based pharmacokinetic modelling"'
Autor:
Nada Abla, Anne Claire Marrast, Elodie Jambert, Naomi Richardson, Stephan Duparc, Lisa Almond, Karen Rowland Yeo, Xian Pan, Joel Tarning, Ping Zhao, Janice Culpepper, Catriona Waitt, Charlotte Koldeweij, Susan Cole, Andrew S. Butler, Sonia Khier, Jörg J. Möhrle, Myriam El Gaaloul
Publikováno v:
Malaria Journal, Vol 23, Iss 1, Pp 1-12 (2024)
Abstract Plasmodium vivax malaria remains a global health challenge, with approximately 6.9 million estimated cases in 2022. The parasite has a dormant liver stage, the hypnozoite, which reactivates to cause repeated relapses over weeks, months, or y
Externí odkaz:
https://doaj.org/article/45b60ab3d99845c694b1be738e16f7c1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Julia Macente, Nina Nauwelaerts, Francesca M. Russo, Jan Deprest, Karel Allegaert, Bart Lammens, Rodolfo Hernandes Bonan, Jessica M. Turner, Sailesh Kumar, Andrea Diniz, Frederico S. Martins, Pieter Annaert
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Sildenafil is a potent vasodilator and phosphodiesterase type five inhibitor, commercially known as Revatio® and approved for the treatment of pulmonary arterial hypertension. Maternal administration of sildenafil during pregnancy is being evaluated
Externí odkaz:
https://doaj.org/article/8ad98c4598d14cb5a091940804d0bb02
Autor:
Leyanis Rodriguez-Vera, Xuefen Yin, Mohammed Almoslem, Karolin Romahn, Brian Cicali, Viera Lukacova, Rodrigo Cristofoletti, Stephan Schmidt
Publikováno v:
Pharmaceutics, Vol 15, Iss 10, p 2486 (2023)
Regulatory agencies worldwide expect that clinical pharmacokinetic drug–drug interactions (DDIs) between an investigational new drug and other drugs should be conducted during drug development as part of an adequate assessment of the drug’s safet
Externí odkaz:
https://doaj.org/article/a264f6e2b35344d99f434b3337e22602
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Tom G. Jacobs, Marika A. de Hoop-Sommen, Thomas Nieuwenstein, Joyce E. M. van der Heijden, Saskia N. de Wildt, David M. Burger, Angela Colbers, Jolien J. M. Freriksen
Publikováno v:
Pharmaceutics, Vol 15, Iss 5, p 1424 (2023)
Dose recommendations for lamivudine or emtricitabine in children with HIV and chronic kidney disease (CKD) are absent or not supported by clinical data. Physiologically based pharmacokinetic (PBPK) models have the potential to facilitate dose selecti
Externí odkaz:
https://doaj.org/article/f0e923f5f4f04bd49f39e94d8c77f92b
Autor:
Min-Soo Kim, Yoo-Kyung Song, Ji-Soo Choi, Hye Young Ji, Eunsuk Yang, Joon Seok Park, Hyung Sik Kim, Min-Joo Kim, In-Kyung Cho, Suk-Jae Chung, Yoon-Jee Chae, Kyeong-Ryoon Lee
Publikováno v:
Pharmaceutics, Vol 15, Iss 3, p 942 (2023)
Enavogliflozin is a sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor approved for clinical use in South Korea. As SGLT2 inhibitors are a treatment option for patients with diabetes, enavogliflozin is expected to be prescribed in various pop
Externí odkaz:
https://doaj.org/article/580c6b225f774237b34dce9ed51ac759
Autor:
Susan A. Charman, Alice Andreu, Helena Barker, Scott Blundell, Anna Campbell, Michael Campbell, Gong Chen, Francis C. K. Chiu, Elly Crighton, Kasiram Katneni, Julia Morizzi, Rahul Patil, Thao Pham, Eileen Ryan, Jessica Saunders, David M. Shackleford, Karen L. White, Lisa Almond, Maurice Dickins, Dennis A. Smith, Joerg J. Moehrle, Jeremy N. Burrows, Nada Abla
Publikováno v:
Malaria Journal, Vol 19, Iss 1, Pp 1-27 (2020)
Abstract Background Modelling and simulation are being increasingly utilized to support the discovery and development of new anti-malarial drugs. These approaches require reliable in vitro data for physicochemical properties, permeability, binding, i
Externí odkaz:
https://doaj.org/article/e55944d6ff034a1fadacb975357d1421
Publikováno v:
Pharmaceutics, Vol 14, Iss 9, p 1957 (2022)
Background: pathophysiological changes such as low cardiac output (LCO) impact pharmacokinetics, but its extent may be different throughout pediatrics compared to adults. Physiologically based pharmacokinetic (PBPK) modelling enables further explorat
Externí odkaz:
https://doaj.org/article/c9eda92e1bbf47d880044504239507de
Autor:
Stefan Willmann, Kirstin Thelen, Dagmar Kubitza, Anthonie W. A. Lensing, Matthias Frede, Katrin Coboeken, Jan Stampfuss, Rolf Burghaus, Wolfgang Mück, Jörg Lippert
Publikováno v:
Thrombosis Journal, Vol 16, Iss 1, Pp 1-12 (2018)
Abstract Background The EINSTEIN-Jr program will evaluate rivaroxaban for the treatment of venous thromboembolism (VTE) in children, targeting exposures similar to the 20 mg once-daily dose for adults. A physiologically based pharmacokinetic (PBPK) m
Externí odkaz:
https://doaj.org/article/cd6a4e691d8a432894fe4658e16270e0